UCB FIRST LOOK: 5Y PsO and 2Y HS data further cement Bimzelx' leadership
Additional data presented at AAD 2025 further cement Bimzelx' leadership in the IL-17 space for PsO and HS. In PsO, efficacy was well maintained from previous 4-year data into the 5-year follow-up with 67.7% PASI100 and 84.9% PASI90. In HS, additional 2-year data saw 55.7% pts with draining tunnels at baseline, a particularly painful manifestation, reaching clearance after two years. We reiterate our confidence in Bimzelx as an rising leader in the dermatology/rheumatology space, and confirm our € 214 TP/Accumulate rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.